Table 3 Adoptive cell therapy (ACT) clinical trials using CRISPR/Cas9 technology for the treatment of cancer. Data extracted from https://clinicaltrials.gov/ (last accessed 6/3/2021)
From: CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy
Clinical Trial Number | Delivery Method | Phase | Target Gene/ Purpose | Cancer Type | Cell Type | Sponsor/Country | Date Posted/ Last Update | Recruitment Status |
|---|---|---|---|---|---|---|---|---|
NCT02793856 | N/A | I | PDCD1-KO | Metastatic Non-small Cell Lung Cancer | Primary T-cells | Peking University/China | 6/8/2016 1/12/2021 | Completed |
NCT02863913 | N/A | I | PDCD1-KO | Stage IV Invasive Bladder Cancer | Primary T-cells | Peking University/China | 8/11/2016 3/6/2019 | Withdrawn |
NCT02867332 | N/A | I | PDCD1-KO | Metastatic Renal Cell Carcinoma | Primary T-cells | Peking University/China | 8/15/2016 3/6/2019 | Withdrawn |
NCT02867345 | N/A | I | PDCD1-KO | Hormone Refractory Prostate Cancer | Primary T-cells | Peking University/China | 8/15/2016 3/6/2019 | Withdrawn |
NCT03044743 | N/A | I/II | PDCD1-KO | Multiple Neoplasms | Ant-EBV CTLs | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School/China | 2/7/2017 5/2/2017 | Recruiting |
NCT03081715 | N/A | I | PDCD1-KO | Esophageal Cancer | Primary T-cells | Hangzhou Cancer Center/China | 3/16/2017 6/12/2019 | Completed |
NCT03538613 | N/A | I/II | CISH-KO | Metastatic Gastrointestinal Cancers | TILs | National Cancer Institute/USA | 6/11/2020 6/16/2020 | Recruiting |
NCT04089891 | N/A | I/II | CISH-KO | Metastatic Gastrointestinal Epithelial Cancer | TILs | Masonic Cancer Center, University of Minnesota/USA | 10/31/2019 8/3/2020 | No Longer Active |
NCT03398967 | N/A | I/II | TRAC, CD52-KO | B cell Lymphoma/Leukemia | CD19/20- or CD19/22- UCART | Chinese PLA General Hospital/China | 1/16/2018 1/16/2018 | Recruiting |
NCT03166878 | Lentiviral (CAR) Electroporation (TCR/B2M) | I/II | TRAC, TRBC, B2M-KO | B cell Lymphoma/Leukemia | CD19-UCART | Chinese PLA General Hospital/China | 5/25/2017 6/23/2017 | Recruiting |
NCT03690011 | N/A | I | CD7-KO | T-cell Malignancies | CD7-CAR T-cells | Baylor College of Medicine/USA | 10/1/2018 3/26/2021 | Not yet recruiting |
NCT03747965 | N/A | I | PDCD1-KO | Multiple Mesothelin Positive Solid Tumors | Anti-mesothelin UCART | Chinese PLA General Hospital/China | 11/20/2018 | Unknown |
NCT03545815 | N/A | I | TRAC, PDCD1-KO | Multiple Mesothelin Positive Solid Tumors | Anti-mesothelin UCART | Chinese PLA General Hospital/China | 6/4/2018 8/10/2020 | Recruiting |
NCT04035434 | Electroporation | I | TRAC-KO | B cell Lymphoma/Leukemia | CD19-UCART (CTX110) | CRISPR Therapeutics AG/USA | 7/29/2019 1/19/2021 | Recruiting |
NCT04037566 | Lentiviral (CAR) Electroporation (HPK1) | I | HPK1-KO | B cell Lymphoma/Leukemia | CD19-CAR T-cells | Xijing Hospital/China | 7/30/2019 7/30/2019 | Recruiting |
NCT03399448 | Electroporation | I | TRAC, TRBC, PDCD1-KO | Multiple Malignancies | NYCE T cells | University of Pennsylvania/USA | 1/16/2018 10/12/2020 | Terminated |